Skip to main content
Thursday, October 29, 2026Oct 29

This story is free to read.

FDA to review safety of inhalable caffeine

photo In this Feb. 7, 2012 file photo, a woman holds an AeroShot inhalable caffeine device in Boston. The Food and Drug Administration will investigate the safety and legality of the product, created by Harvard biomedical engineering professor David Edwards.

BOSTON – U.S. Food and Drug Administration officials plan to investigate whether inhalable caffeine sold in lipstick-sized canisters is safe for consumers and if its manufacturer was right to brand it as a dietary supplement.

AeroShot went on the market late last month in Massachusetts and New York, and it’s also available in France. Consumers put one end of the canister in their mouths and breathe in, releasing a fine powder that dissolves almost instantly.

Each grey-and-yellow plastic canister contains B vitamins, plus 100 milligrams of caffeine powder, about the equivalent of the caffeine in a large cup of coffee.

AeroShot inventor, Harvard biomedical engineering professor David Edwards, said the product is safe and doesn’t contain taurine and other common additives used to enhance the caffeine effect in energy drinks.

AeroShot didn’t require FDA review before hitting the U.S. market because it’s sold as a dietary supplement. But New York’s U.S. Sen. Charles Schumer said he met with FDA Commissioner Dr. Margaret Hamburg, and she agreed to review the safety and legality of AeroShot.